Molecular data
| Physical form | Lyophilized powder blend |
|---|---|
| Available sizes | 10mg / 10mg |
How it works
-
MOTS-c
AMPK Signalling
MOTS-c is a mitochondrial-derived peptide encoded in the mitochondrial genome. AMPK pathway activation and metabolic-regulation endpoints are the characterised readouts.
- Mitochondrial-derived peptide
- AMPK pathway activation
- Metabolic regulation endpoints
-
SS-31
Cardiolipin Binding
SS-31 binds cardiolipin on the inner mitochondrial membrane. Membrane stabilisation and preserved cristae architecture are the characterised endpoints, alongside reduced reactive oxygen species.
- Cardiolipin binding
- Inner-membrane stabilisation
- Reactive oxygen species endpoints
-
Combined
Two Mitochondrial Angles
The vial pairs a signalling-side peptide with a membrane-side peptide. The two are characterised separately and no interaction data exists for the pair.
- Signalling and membrane arms
- Matched handling
- Interaction not characterised
What the research shows
-
Cell Biology
Mitochondrial Function
Both peptides are studied for mitochondrial function from different mechanistic angles.
-
Metabolic
Metabolic Regulation
MOTS-c is characterised for AMPK-pathway activation in metabolic models.
-
Cell Biology
Oxidative Stress Models
SS-31 is studied for reactive-oxygen-species endpoints and membrane integrity.
-
Methods
Parallel Protocols
One vial holds both peptides under matched handling.
Specification
| Components | MOTS-c + SS-31 |
|---|---|
| Content | 20 mg per vial (10 mg of each component) |
| MOTS-c | 16-amino acid mitochondrial-derived peptide |
| SS-31 | Cardiolipin-targeting tetrapeptide |
| Form | Lyophilized powder blend |
| Purity | ≥99% by HPLC |
| Appearance | White to off-white powder |
| Solubility | Water-soluble |
| Storage | -20°C, protected from light |
| Classification | Research use only |
Frequently asked questions
Why combine MOTS-c and SS-31?
They approach mitochondrial research from different angles: MOTS-c through AMPK signalling, SS-31 through cardiolipin binding and inner-membrane stabilisation. One vial holds both under matched handling.
Has the combination been characterised as a single formulation?
No. Each peptide is characterised separately and no interaction data exists for the pair.
How does this differ from buying MOTS-c and SS-31 separately?
The separate products let you control each peptide's quantity independently and are offered in 10, 30 and 50 mg. This vial fixes the ratio at 10 mg and 10 mg.
What purity is documented?
Each lot is analysed by reverse-phase HPLC and released at ≥99%, with a Certificate of Analysis.
How is it stored?
Store lyophilized at -20°C for long-term stability, protected from light and moisture, and avoid repeated freeze-thaw cycles.
Related monographs
For laboratory research use only. Not a drug, supplement, or medical product; not for human or animal use. All findings referenced are from published preclinical/laboratory research.